E-LETTERS: COMMENTS AND RESPONSES

Reply letter to "COVID-19 and Recurrent Status Epilepticus"

Giada Pauletto¹, Annacarmen Nilo², Cristian Deana³, Lorenzo Verriello¹, Ilaria Del Negro^{2,5}, Christian Lettieri¹, Luigi Vetrugno⁴, Mariarosaria Valente^{2,5}, Gian Luigi Gigli^{2,5}

¹Neurology Unit, Department of Neurosciences, S. Maria della Misericordia University Hospital, Udine, Italy; ²Clinical Neurology Unit, Department of Neurosciences, S. Maria della Misericordia University Hospital, Udine, Italy; ³Anesthesia and Intensive Care, S. Maria della Misericordia University Hospital, Udine, Italy; ⁴Clinical Anesthesia and Intensive Care, Department of Medicine (DAME), University of Udine Medical School, Udine, Italy; ⁵Department of Medicine (DAME), University of Udine, Italy

To the Editor,

We thank dr. Rjittika Mungmunpuntipantip and prof. Viroj Wiwanitkit for the comments on our article entitled "Recurrent Status Epilepticus and SARS-CoV-2 infection: the perfect storm" (1).

We agree that the clinical association between Status Epilepticus (SE) and SARS-CoV-2 infection is intriguing.

In a previous article, we reviewed the possible pathogenetic mechanisms of Central and Peripheral Nervous System complications induced by SARS-CoV-2. Direct viral invasion, micro thrombosis, hypoxemia, systemic citokine storm and other factors strictly related with critically ill-patients have been described (2).

Robust clinical and experimental evidence highlights that the activation of inflammatory cascade during SE may play an important role in sustaining or relapsing seizures and detrimental neurological outcome (3).

Indeed, increased citokine levels have been reported in single cases or in case series describing the occurrence of SE as a consequence of Covid-19 (4).

Furthermore, inflammation may induce a procoagulant state, which, together with blood hyperviscosity and coagulation dysfunction are pathogenetic mechanisms for cerebro-vascular COVID-19 related complication. However, we believe that, considering all the pathological pathways involved and metabolic derangements occurring during SE, it is hard to say which has the greatest influence in determining and maintaining the SE itself.

Conflict of Interest: Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article

References

- Pauletto G, Nilo A, Deana C, et al. Recurrent Status Epilepticus and SARS-CoV-2 infection: the perfect storm. Acta Biom 2021; Vol 92, N.5: e2021208
- Deana C, Verriello L, Pauletto G, et al. Insights into neurological dysfunction of critically ill COVID-19 patients. Trends in Anaesthesia & Critical Care 2021; 36:30–8. doi: 10.1016/j.tacc.2020.09.005. Epub 2020 Sep 15. PMCID: PMC7490585.
- 3. Vezzani A, Dingledine R, Rossetti AO. Immunity and inflammation in status epilepticus and its sequelae: possibilities for therapeutic application. Expert Rev Neurother 2015;15(9):1081-92.doi:10.1586/14737175.2015.1079130. PMID: 26312647; PMCID: PMC4767891.
- 4. M. Belluzzo, A. Nilo, M. Valente, G. L. Gigli. New-onset status epilepticus in SARS-CoV-2 infection: a case series. Neurol Sci 2021 Aug 16: 1-6. doi: 10.1007/s10072-021-05536-0

Correspondence:

Received: 29 November 2021 Accepted: 20 December 2021

Annacarmen Nilo

Clinical Neurology Unit, Department of Neurosciences, Santa Maria della Misericordia University Hospital, Piazzale S. Maria della Misericordia 15, Udine (UD), 33100, Italy.

Phone: 0039-0432559020/0039-3476052819.

E-mail: annacarmen.nilo@gmail.com